MEP89008A - Novi analog ciloksporina za formiranje mikroemulzionih prekoncentrata - Google Patents

Novi analog ciloksporina za formiranje mikroemulzionih prekoncentrata

Info

Publication number
MEP89008A
MEP89008A MEP-890/08A MEP89008A MEP89008A ME P89008 A MEP89008 A ME P89008A ME P89008 A MEP89008 A ME P89008A ME P89008 A MEP89008 A ME P89008A
Authority
ME
Montenegro
Prior art keywords
microemulsion preconcentrates
novel cyclosporin
cyclosporin analog
cyclosporin
analog microemulsion
Prior art date
Application number
MEP-890/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Selvaraj Naicker
Randall W Yatscoff
Robert T Foster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MEP89008A publication Critical patent/MEP89008A/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
MEP-890/08A 2001-10-19 2002-10-17 Novi analog ciloksporina za formiranje mikroemulzionih prekoncentrata MEP89008A (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US37059702P 2002-04-05 2002-04-05
PCT/CA2002/001561 WO2003032949A1 (en) 2001-10-19 2002-10-17 Novel cyclosporin analog microemulsion preconcentrates

Publications (1)

Publication Number Publication Date
MEP89008A true MEP89008A (hr) 2011-12-20

Family

ID=26994747

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-890/08A MEP89008A (hr) 2001-10-19 2002-10-17 Novi analog ciloksporina za formiranje mikroemulzionih prekoncentrata

Country Status (29)

Country Link
US (5) US7060672B2 (hr)
EP (2) EP1435910B9 (hr)
JP (3) JP2005506990A (hr)
KR (1) KR100978836B1 (hr)
CN (1) CN1274294C (hr)
AR (1) AR036852A1 (hr)
AT (1) ATE437629T1 (hr)
AU (1) AU2002333098B2 (hr)
BR (1) BR0213661A (hr)
CA (1) CA2461730C (hr)
CO (1) CO5580835A2 (hr)
DE (1) DE60233150D1 (hr)
DK (1) DK1435910T3 (hr)
ES (1) ES2330625T3 (hr)
HK (1) HK1062525A1 (hr)
HR (1) HRP20040354B1 (hr)
IL (3) IL160761A0 (hr)
MA (1) MA26221A1 (hr)
ME (1) MEP89008A (hr)
MX (1) MXPA04003623A (hr)
MY (1) MY145753A (hr)
NO (1) NO20042028L (hr)
NZ (1) NZ531946A (hr)
PL (1) PL206018B1 (hr)
PT (1) PT1435910E (hr)
RU (1) RU2317067C2 (hr)
TN (1) TNSN04070A1 (hr)
WO (1) WO2003032949A1 (hr)
ZA (1) ZA200402268B (hr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
WO2004082629A2 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
WO2006039164A2 (en) * 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006041631A2 (en) * 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
EP1996067B1 (en) * 2005-05-19 2013-04-10 The Board Of Governors For Higher Education Monitoring cyclosporine in saliva
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
CA2645080A1 (en) * 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
EP2077834A2 (en) * 2006-10-31 2009-07-15 Wyeth Formulations of phospholipase enzyme inhibitors
CL2007003143A1 (es) * 2006-10-31 2008-01-25 Wyeth Corp Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion.
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
CN107080734B (zh) 2008-03-20 2020-10-30 维尔恩公司 包含生育酚的peg衍生物的乳剂
EP2268274B1 (en) 2008-03-20 2012-05-16 Virun, Inc. Vitamin e derivatives and their uses
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN102458370A (zh) 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
CN102652015B (zh) * 2009-12-10 2016-08-03 默克专利有限公司 包含寡肽、优选西仑吉肽的药物组合物
KR101622441B1 (ko) * 2010-03-23 2016-05-18 버런, 아이엔씨. 자당 지방산 에스테르를 포함하는 나노에멀전
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20110319467A1 (en) * 2010-06-23 2011-12-29 Bhiku Patel Absorption Enhancement of Statins and Omega Fatty Acids
RU2566984C2 (ru) * 2010-06-25 2015-10-27 Фирмениш Са Система доставки пищевых компонентов
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
US9044394B2 (en) 2010-10-18 2015-06-02 PruGen IP Holdings, Inc. Bioavailability enhancement delivery composition
RU2630690C9 (ru) 2010-12-15 2017-12-28 КонтраВир Фармасьютикалз, Инк. МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ
US8609684B2 (en) 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
US8937081B2 (en) 2011-12-12 2015-01-20 PruGen IP Holdings, Inc. Statin bioavailability enhancement delivery composition
CA3050298A1 (en) 2012-08-24 2014-02-27 Sun Pharma Global Fze Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
JP6831704B2 (ja) * 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
CN109843316A (zh) 2016-02-29 2019-06-04 太阳制药全球公司 含有环孢菌素的局部制剂及其用途
US20200003785A1 (en) 2016-12-01 2020-01-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019077123A1 (en) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
MX2021006010A (es) * 2018-11-26 2021-09-21 Hepion Pharmaceuticals Inc Formulaciones farmaceuticas para analogos de ciclosporina.
WO2020115262A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
SG11202107606VA (en) 2019-01-15 2021-08-30 Inst Nat Sante Rech Med Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
EP3981432B1 (en) 2019-03-27 2024-07-31 Tokyo Medical University Therapeutic agent for wolfram syndrome
KR102449537B1 (ko) * 2022-01-27 2022-10-05 주식회사 나노메디팜 근적외선을 이용하여 진단 생검 또는 종양 제거 수술 중에 종양 식별과 절제면 구분을 위한 종양 표적 진단 조영제
WO2024153636A1 (en) 2023-01-17 2024-07-25 Institut National de la Santé et de la Recherche Médicale Vasorin as a biomarker and biotarget in nephrology

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (hr) 1975-11-04 1979-12-28 Sandoz Ag
DE2819094A1 (de) 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
DE3260468D1 (en) 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
HU205861B (en) 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
DE3884470T2 (de) 1987-06-17 1994-03-10 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel.
DE3851268T2 (de) 1987-06-19 1995-01-26 Sandoz Ag Zyklische Peptolide.
ES2033086T3 (es) 1988-01-29 1993-03-01 Sankyo Company Limited Un procedimiento para la preparacion de una composicion farmaceutica.
HU201567B (en) 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5681964A (en) 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
EP0484281B2 (en) 1990-11-02 2000-11-22 Novartis AG Cyclosporins
GB9105705D0 (en) 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
AU657961B2 (en) 1991-04-19 1995-03-30 Nexstar Pharmaceuticals, Inc. Pharmaceutical formulation and process
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5248499A (en) 1991-10-07 1993-09-28 Genentech, Inc. Control of microbial infections in transplant patients
US5759566A (en) 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
US5654000A (en) 1992-07-28 1997-08-05 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
DK1033128T4 (da) 1993-09-28 2012-03-19 Scherer Gmbh R P Blød gelatinekapselfremstilling
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2185803C (en) 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
FI100692B (fi) 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5739105A (en) 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
CH686865A5 (de) 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
US5635159A (en) 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
GB9512100D0 (en) 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
AU692255B2 (en) 1995-04-24 1998-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
US5693336A (en) 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US5656287A (en) 1995-06-07 1997-08-12 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
AU709548B2 (en) * 1995-08-25 1999-09-02 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
CZ288631B6 (cs) 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
KR980008239A (ko) 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
CA2261666C (en) 1996-07-30 2010-09-14 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
CZ288739B6 (cs) 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky
CZ267796A3 (cs) 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
CA2185600A1 (en) 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
US5798333A (en) 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
IL131609A0 (en) 1997-03-12 2001-01-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
NZ314702A (en) 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
US6258783B1 (en) 1997-04-29 2001-07-10 Bernard Charles Sherman Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
IN188719B (hr) 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6008191A (en) 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
WO1999012640A1 (en) * 1997-09-09 1999-03-18 Select Release, L.C. Coated particles, methods of making and using
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
US6028067A (en) 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
WO2001028519A1 (de) * 1999-10-20 2001-04-26 Vesifact Ag Mikroemulsion-prekonzentrate und mikroemulsionen
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート

Also Published As

Publication number Publication date
WO2003032949A1 (en) 2003-04-24
NZ531946A (en) 2005-09-30
KR100978836B1 (ko) 2010-08-30
EP1435910A1 (en) 2004-07-14
IL195892A (en) 2013-09-30
CN1274294C (zh) 2006-09-13
CA2461730A1 (en) 2003-04-24
MXPA04003623A (es) 2004-12-02
HRP20040354B1 (en) 2012-10-31
RU2317067C2 (ru) 2008-02-20
ZA200402268B (en) 2005-05-25
IL160761A0 (en) 2004-08-31
DK1435910T3 (da) 2009-11-09
PL206018B1 (pl) 2010-06-30
DE60233150D1 (de) 2009-09-10
RU2004110936A (ru) 2005-05-27
PT1435910E (pt) 2009-09-07
TNSN04070A1 (en) 2006-06-01
US7829533B2 (en) 2010-11-09
EP1435910B9 (en) 2010-02-03
AR036852A1 (es) 2004-10-06
JP2009073850A (ja) 2009-04-09
EP1435910B1 (en) 2009-07-29
JP2005506990A (ja) 2005-03-10
CO5580835A2 (es) 2005-11-30
NO20042028L (no) 2004-05-14
US20110136744A1 (en) 2011-06-09
HK1062525A1 (en) 2004-11-12
CN1571657A (zh) 2005-01-26
US20030171264A1 (en) 2003-09-11
US7060672B2 (en) 2006-06-13
ATE437629T1 (de) 2009-08-15
BR0213661A (pt) 2004-10-26
US20060217309A1 (en) 2006-09-28
HRP20040354A2 (en) 2005-02-28
MY145753A (en) 2012-03-30
KR20050037418A (ko) 2005-04-21
PL370560A1 (en) 2005-05-30
US20140249092A1 (en) 2014-09-04
CA2461730C (en) 2012-05-15
ES2330625T3 (es) 2009-12-14
EP2116228A1 (en) 2009-11-11
MA26221A1 (fr) 2004-07-01
AU2002333098B2 (en) 2006-03-16
JP2012158609A (ja) 2012-08-23
IL160761A (en) 2010-11-30
US7429562B2 (en) 2008-09-30
US20090054311A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MEP89008A (hr) Novi analog ciloksporina za formiranje mikroemulzionih prekoncentrata
ATE312843T1 (de) Neues cyclosporin mit verbesserter wirkung
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
RS105704A (sr) Kiseli preparati insulina sa poboljšanom stabilnošću
YU73503A (sh) Preparati insulina koji ne sadrže cink ili sadrže male količine cinka i koji imaju poboljšanu stabilnost
CO5050376A1 (es) Estructureas novedosas utiles como hojas limpiadoras de pol- vo pelusa, cabello, arena, migajas de alimentos, pasta y similares
FR2757521B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1313467T3 (da) Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
DK0758231T3 (da) Farmaceutiske præparater på basis af derivater tilhørende taxanklassen
ATE397936T1 (de) Therapeutische verfahren unter verwendung von pflanzlichen zusammensetzungen
ATE500323T1 (de) Subtilisin-variante
AU1593001A (en) Recombinant gelatin in vaccines
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
IL155788A (en) A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
DE60042816D1 (de) T-helferzellen-epitope
DE69900495D1 (de) Flüssigkristalle des cyclosporins
BG103818A (en) Pharmaceutical composition
PT917460E (pt) Formulacoes de ciclosporina
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE385805T1 (de) Neue peptide
HUP0000344A2 (hu) Lamivudint és zidovudint tartalmazó gyógyszerkészítmények
AP9901529A0 (en) Conformationally constrained LH-RH analogues, their uses and pharmaceutical compositions containing them.
AU2003260816A1 (en) Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
UY27501A1 (es) Nuevas formulaciones de análogos de ciclosporina